Sonio, a French medtech specializing in pregnant people and children’s health, is today finalizing a series A fundraising of $14 million following the initial commitment of the EIC Fund (European Innovation Council) last December.
This round is led by Cross Border Impact Ventures, a North American impact fund dedicated to the health of women and children, and the Elaia funds, French Tech Seed managed on behalf of the State by Bpifrance in the framework of France 2030, OneRagtime, as well as business angels very active in the health field, including Dominique Gaillard (former president of France Invest), Alain Decombe (Dechert) and Yann Fleureau (founder of Cardiologs), who renew their trust.
True to its mission to improve access to quality pregnancy monitoring for all, Sonio will use this fundraising to continue to improve its SaaS solution, initiate its commercial development in the United States, and adapt its technology for the use of portable ultrasound scanners.
“Sonio has created an innovative platform that empowers fetal ultrasound technology, enhancing the effectiveness and efficiency of fetal medicine specialists. Additionally, it aims to bridge the increasing shortage of specialized healthcare workers worldwide. We take pride in leading this significant round of financing, as it contributes to the early growth of this venture.” Says Annie Thériault, Managing Partner at Cross-Border Impact Ventures.
The Company has developed the first SaaS, agnostic and interoperable, to automate ultrasound reporting, while providing image quality control and detection of potential anomalies using AI. Sonio will continue to enrich its artificial intelligence for image recognition in order to extend the number of automatically recognized images, to be able to check their quality, and to help detect anomalies, and will integrate data into its multimodal platform imaging and genomics.
Sonio has always had the ambition to offer quality care to all pregnant people and all children, including in the poorest regions, particularly affected by maternal mortality. Of the 287,000 women who died in such circumstances in 2020, 70% were recorded in sub-Saharan Africa. Sonio’s technology, made available to manufacturers of portable ultrasound scanners, will enable healthcare personnel to carry out ultrasounds all over the world to high and verified quality standards. Sonio has identified the mission of meeting the specific needs of these new equipment manufacturers both to equip new non-expert practitioners in developed countries (emergency physicians, general practitioners/midwives in medical deserts) and in developing countries. development.
Cécile Brosset, CEO and co-founder of Sonio states: “This lifting is a pivotal step in the development of Sonio. By supporting our technological and commercial growth, it makes it possible to achieve our mission. I am fortunate to be surrounded by a team of deeply committed experts, and I would like to thank them. Our board of directors is today in the image of Sonio, inscribed in the diversity of men and women, international, and in search of a model of both impact and growth. In a financing universe largely dominated by men, I am delighted to have found partners so aligned with our ambitions and who understood and valued Sonio’s mission as well as its strategy and rapid execution capacity.”
About Sonio
Sonio is an Artificial Intelligence solution for prenatal screening and diagnosis with over five years of research and collaborations between leading experts in fetal medicine and artificial intelligence. Sonio’s goal is to support the analysis of practitioners in prenatal screening and diagnosis by assuring the completeness of their examination and increasing the accuracy of their patient scan results.
To learn more about Sonio, visit our website https://sonio.ai/us/
